Research Article
Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years
Table 6
Safety parameters of men receiving testosterone treatment (means ± SD).
| Visit month | | Prostate volume (mL) | | PSA (ng/dL) | | Residual volume (mL) | | IPSS score | | Hemoglobin (g/L) | | Hematocrit (%) | | ALT (U/L) | | AST (U/L) |
| 0 month | 45 | 19.8 ± 7.4 | 45 | 0.96 ± 1.05 | 41 | 26.0 ± 17.0 | 45 | 3.1 ± 3.0 | 45 | 14.6 ± 0.6 | 45 | 44.4 ± 2.0 | 45 | 44.8 ± 21.7 | 45 | 43.7 ± 20.9 | 12 months | 16 | 21.9 ± 9.8 | 20 | 1.26 ± 1.00 | 39 | 18.7 ± 14.2 | 43 | 2.1 ± 2.1 | 44 | 14.9 ± 0.5 | 44 | 46.4 ± 2.2 | 44 | 29.6 ± 14.2 | 44 | 27.7 ± 12.6 | 24 months | 10 | 26.8 ± 10.6 | 17 | 1.45 ± 1.05 | 33 | 15.5 ± 10.6 | 35 | 1.9 ± 1.8 | 36 | 15.0 ± 0.4 | 36 | 47.7 ± 1.7 | 36 | 26.6 ± 11.9 | 36 | 26.8 ± 9.6 | 36 months | 12 | 26.9 ± 9.2 | 15 | 1.40 ± 1.12 | 29 | 14.7 ± 9.0 | 32 | 1.8 ± 1.4 | 32 | 15.1 ± 0.4 | 32 | 48.4 ± 1.8 | 32 | 24.6 ± 8.4 | 32 | 25.6 ± 7.9 | 48 months | 8 | 29.3 ± 10.6 | 9 | 1.37 ± 1.19 | 22 | 13.0 ± 5.5 | 25 | 1.4 ± 0.9 | 25 | 15.1 ± 0.4 | 25 | 48.4 ± 1.4 | 25 | 25.2 ± 5.6 | 25 | 25.4 ± 5.9 | 60 months | 3 | 27.7 ± 16.2 | 4 | 1.59 ± 1.20 | 10 | 13.5 ± 6.7 | 10 | 1.8 ± 1.1 | 10 | 15.1 ± 0.4 | 10 | 48.0 ± 1.8 | 10 | 22.8 ± 5.2 | 10 | 22.4 ± 4.8 | 72 months | 3 | 24.3 ± 16.7 | 3 | 1.04 ± 1.21 | 4 | 12.5 ± 5.0 | 4 | 1.8 ± 1.0 | 4 | 15.2 ± 0.3 | 4 | 49.0 ± 1.8 | 4 | 22.0 ± 3.5 | 4 | 21.0 ± 2.9 | Difference 60 months-baseline | | 3.1 ± 0.51 | | 0.15 ± 0.092 | | −19.12 ± 2.231 | | −2.5 ± 0.41 | | 0.54 ± 0.11 | | 3.8 ± 0.41 | | −28.4 ± 2.51 | | −25.5 ± 2.31 |
|
|
. Non significant. PSA: Prostate specific antigen. IPSS: International prostate symptom score. ALT: Alanine aminotransferase. AST: Aspartate aminotransferase.
|